-
ECB opens door to September rate-hike as Iran war flares up
-
Oil soars to $100 on fresh Mideast attacks
-
World Bank estimates Venezuela quakes caused $19.6 bn in damage
-
Coal-fired power generation rising globally on Mideast war: IEA
-
Italy's far-right line up to defend jeweller who killed robbers
-
Premier League champions Arsenal sign Greece winger Tzolis from Brugge
-
AI-led boom in IPOs raises concerns about a bust
-
French Jewish DJ sues after activists disrupt gig: lawyer
-
Klopp expected to be named new Germany coach on Friday
-
Venice film festival promises Pattinson, Oasis and Musk doc
-
ECB holds rates as Iran war flare-up threatens to drive prices higher
-
ASEAN calls for open straits as US-Iran war casts shadow
-
MEXC's "Kickoff Fest" Trading Event Concludes with Top Individual Reward of 27,352 USDT
-
Ford and Geely to form joint venture at struggling Spain plant
-
Oil soars close to $100 on fresh Mideast attacks
-
Russia warns US against Ukraine arms sales in Manila meeting
-
India's angry Gen Z protesters say Modi must fix accountability
-
New UK PM announces tax cut for struggling pubs
-
Barca sign Adeyemi from Borussia Dortmund
-
Supporters flood India's 'cockroach' protesters with food
-
EasyJet profits nosedive on Mideast war
-
Modi vows punishment for exam leaks fuelling India protests
-
EU fines Google 890 mn euros, risking US fury
-
Norway set to make formal complaint to FIFA over Balogun red card saga
-
France evacuates thousands of tourists as fire rages in pine forest
-
Floods in northeast India kill at least 41
-
French Jewish DJ sues after activists disrupt stage show: lawyer
-
Nestle siphons off bottled water business into joint venture
-
Nokia says AI, cloud boosted sales in second quarter
-
Hundreds hospitalised in Japan heatwave 'disaster'
-
Repsol says profit more than triples on higher oil prices
-
Renault says sales stalled in first half
-
TotalEnergies says profit doubled on Mideast war
-
EasyJet says profits nosedive on Mideast war
-
Giant swing on Swiss peak aims to boost summer tourism as Alps warm
-
Modi vows punishment for exam fraud fuelling India protests
-
ASEAN to call for open straits as US-Iran war casts shadow
-
Six candidates in race to lead UN set for televised debate
-
AI catches up with humans to score 100% at top maths contest
-
Comic-Con kicks off with Marvel's return
-
South Korea election office raided in fake turnout figures probe: investigators
-
Dutch riders dreaming of crazy party corner of Alpe d'Huez
-
Killer whales: orcas blow fish to bits 'for fun', study finds
-
Houthis target Red Sea shipping as US hits Iran
-
Deadly wildfires force thousands from homes in parts of Europe
-
Record-equalling Red Sox streak halted at 15 wins
-
Tech bounce lifts Asia stocks, oil extends gains on US-Iran fears
-
Messi-less Miami beat Fire 3-2 to spoil Lewandowski's MLS debut
-
Surrounded by militias, Sudanese fear endless cycle of war
-
Mercedes expect Hungary challenge from Hamilton and Ferrari
The scientist rewriting DNA, and the future of medicine
A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.
A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.
He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.
He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.
"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.
- Correcting the code -
DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.
Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.
It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.
"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.
That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.
Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.
These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.
In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.
While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.
"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.
- Cystic fibrosis hope -
Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.
About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.
To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.
If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.
Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."
Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.
Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.
"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."
This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).
"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."
P.Staeheli--VB